| Mr Christopher Michael Lavin, LADC, LCPC | |
|
Ima Europe Unit 29353, Box 200, Apo, AE 09014 | |
| (496) 221-5789 | |
| Not Available |
| Full Name | Mr Christopher Michael Lavin |
|---|---|
| Gender | Male |
| Speciality | Counselor - Addiction (substance Use Disorder) |
| Location | Ima Europe Unit 29353, Apo, Armed Forces Europe |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477691020 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YA0400X | Counselor - Addiction (substance Use Disorder) | LC506 (Maine) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Christopher Michael Lavin, LADC, LCPC Ima Europe Unit 29353, Box 200, Apo, AE 09014 Ph: () - | Mr Christopher Michael Lavin, LADC, LCPC Ima Europe Unit 29353, Box 200, Apo, AE 09014 Ph: (496) 221-5789 |
News Archive
Patients with chronic subjective dizziness that is related to anxiety may substantially benefit from a short course of cognitive behavioral therapy, report researchers.
Officials with the Centers For Medicare & Medicaid Services published the second stage of "meaningful-use" rules for adoption of electronic medical records Thursday, laying out requirements for better digital communication among doctors and expanded patient access to records, in order for doctors and hospitals to get incentive payments.
New technologies and methods are spurring a renaissance in the study of organogenesis. Organogenesis, essentially the process through which a group of cells becomes a functioning organ, has important connections to biological processes at the cellular and developmental levels, and its study offers great potential for medical treatments through tissue engineering approaches.
Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. Prolia, the first and only FDA-approved RANK Ligand inhibitor, is an every six month 60 mg subcutaneous injection administered by a health care professional.
› Verified 4 days ago
Mr. Michael Alvin Reed, LPC, NCACII, CACII Counselor Medicare: Not Enrolled in Medicare Practice Location: Usag Wiesbaden, Unit 29623, Bldh 1526, Apo, AE 09096 Phone: 061-170-51710 Fax: 061-170-55216 | |
Dr. Richard John Wargel, LMHC, LCDC, NCP Counselor Medicare: Not Enrolled in Medicare Practice Location: Army Substance Abuse Program, Adco, Apo, AE 09114 Phone: 011-499-641831710 Fax: 011-499-641836813 | |
Kathleen Nicol, LICSW Counselor Medicare: Not Enrolled in Medicare Practice Location: Unit 33100 Box Landstuhl, Apo, AE 09180 Phone: 314-590-4058 | |
James P. Bruner, LPC, LICDC Counselor Medicare: Not Enrolled in Medicare Practice Location: Ima-e, Sfim-eu-hr (saic-asacs0, Unit 29353 Box 200, Apo, AE 09014 Phone: 011-496-221163912 Fax: 011-496-221578943 | |
Elizabeth Schwoch, LCSW Counselor Medicare: Not Enrolled in Medicare Practice Location: Usag Hohenfels, Cmr 414 Box 2353, Apo, AE 09173 Phone: 480-525-0284 | |
Mrs. Lisa Jane Remey, LPC, RPT, NCC Counselor Medicare: Not Enrolled in Medicare Practice Location: Psc 2 Box 6496, Apo, AE 09012 Phone: 520-495-4259 | |
Ms. Candace Dawn Merritt, LCSW, LAC Counselor Medicare: Not Enrolled in Medicare Practice Location: Cmr 454 Box 3178, Cmr 454 Box 3178, Apo, AE 09250 Phone: 004-917-19434672 |